The Janssen vaccine, from the American laboratory Johnson & Johnson, is set to be the fourth vaccine authorized on the European market to fight against Covid-19.

A treatment which presents a real advantage compared to its competitors, since it requires only one dose, against two currently, and is kept in simple fridges.

DECRYPTION

It is one more vaccine in the European arsenal to fight against Covid-19.

The serum from the American laboratory Johnson & Johnson, called Janssen, receives this Thursday the approval of the European Medicines Agency, making it the fourth treatment authorized on our market.

And this vaccine presents a real advantage over its competitors, since it only requires a single dose to confer immunity.

>> Find Europe midi every day in replay and podcast here

Efficiency of at least 85%

This Janssen treatment is made from a harmless human virus, to which genetic instructions have been added to educate the body to fight SARS-CoV2.

As a result, with a single dose, its effectiveness is 85% against severe forms 28 days after the injection, and this increases further in the days that follow.

Another advantage of this vaccine, it would even be effective against variants.

These good results should therefore allow vaccination twice as fast and on a large scale, because this serum is also easy to store in a simple fridge.

As for the people targeted to receive this treatment, they are a priori the same as for the AstraZeneca vaccine, that is to say those under 75 years of age, whose vaccination is done in town by doctors and pharmacists.

CORONAVIRUS ESSENTIALS

> Covid-19: is there really a risk of contamination outside?

> Coronavirus: why can a PCR test be positive one month after infection?

> Are private parties really prohibited with the curfew?

> The English variant would cause slightly different symptoms

> Audio, webcams ... When technology adapts to teleworking

In France, the Haute Autorité de Santé (HAS) must specify its conditions of use on Friday or Saturday.

But unfortunately, even if all the lights are green, it should not be possible to inject it in France before April, the date of receipt of the first delivery of a million doses.